Pasithea Therapeutics (KTTA) announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology, ASCO, taking place May 30 – June 3, 2025, in Chicago, Illinois. The Company will present updated interim clinical data from its ongoing Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA: